Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,025 recruiting studies in this area right now.
By phase
- Not applicable2,810
- Phase 2752
- Phase 1523
- Phase 3382
- Phase 1/Phase 2296
- Phase 4203
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,192
- Melanoma174
- Metastatic Breast Cancer138
- Rheumatoid Arthritis131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Breast Neoplasms111
- Triple Negative Breast Cancer110
- Colorectal Cancer94
- Ovarian Cancer91
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer59
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Novartis Pharmaceuticals49
- Memorial Sloan Kettering Cancer Center48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University34
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California408
- Arizona150
- Alabama129
- Florida126
- New York110
- Texas106
- Maryland94
- Massachusetts87
- Pennsylvania72
- North Carolina68
Recruiting studies5,025 total
- NCT06699121RecruitingPhase 2
Testing LB-P8 for people with primary sclerosing cholangitis
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Sacramento, CaliforniaAges 18–75 - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06701513Recruiting
Real-world study of deucravacitinib for plaque psoriasis
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
AmiensAges 18 years+ - NCT06698796RecruitingPhase 3
Study of dazukibart for ongoing idiopathic inflammatory myopathies
This trial studies the long-term effects of dazukibart in people who completed an earlier study for idiopathic inflammatory myopathies (a group of rare conditions causing muscle inflammation and weakness). It helps researchers understand how well the medicine works over a longer period.
Glendale, ArizonaAges 18 years+ - NCT06703398RecruitingPhase 2
Study of GC101 TIL for advanced melanoma
This trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. It involves taking immune cells from a tumor, growing them in a lab, and giving them back to fight the cancer.
BeijingAges 18–75 - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT06702293Recruiting
A therapy app to help with itch from skin conditions
This trial tests a mobile app designed to help reduce itching and related symptoms for people with psoriasis, eczema, or chronic hives. If you have moderate to severe itch and can use an English-language app, this study might be for you.
SingaporeAges 16 years+ - NCT06694519Recruiting
Radiofrequency and exercise for pelvic floor issues after breast cancer
This trial tests whether radiofrequency therapy combined with exercise can help with pelvic floor problems like pain, urgency, or incontinence that some women have after breast cancer treatment.
Elche, Spain / ValenciaAges 18 years+ - NCT06704945RecruitingPhase 3
Skipping armpit surgery after good chemo response
This trial tests whether it's safe to skip armpit surgery in people whose breast cancer has responded well to chemotherapy and whose lymph nodes appear cancer-free on ultrasound. It aims to reduce side effects like arm swelling while still controlling the cancer.
SeoulAges 19 years+ - NCT06694181Recruiting
Safe and explainable AI for heart, sepsis, and breast cancer patients
This trial uses artificial intelligence (AI) to create prediction models for three groups: cardiology patients, sepsis patients, and breast cancer patients. It aims to make these models safe and easy to understand for doctors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06371274Recruiting
Oral vitamin A drug plus immunotherapy for advanced triple-negative breast cancer
This trial tests a combination of an oral vitamin A-based drug (all-trans retinoic acid) and an immunotherapy (toripalimab) for people with advanced triple-negative breast cancer that hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink or control the cancer.
Hangzhou, Zhejiang Province, P.R. ChinaAges 18 years+ - NCT06236932Recruiting
Infection risk in obesity study
This study looks at how obesity and related conditions affect your body's ability to fight infections. It may help find ways to prevent illness in people with obesity.
NaplesAges 18–65 - NCT06682195RecruitingPhase 2
Chemo plus toripalimab before surgery for TNBC
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
Nanchang, JiangxiAges 18–70 - NCT06688838Enrolling by invitation
JAK inhibitor for Blau syndrome
This trial tests a new oral drug that blocks inflammation in people with Blau syndrome, a rare genetic condition causing joint, eye, and skin problems. The goal is to see if the drug can reduce symptoms and improve quality of life.
Wuhan, HubeiAges Any age - NCT06690840RecruitingPhase 2
Atezolizumab plus chemo for advanced triple-negative breast cancer
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
Monza, MonzaAges 18 years+ - NCT06683755RecruitingPhase 1/Phase 2
A study of three immunotherapy drugs for advanced melanoma
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Houston, TexasAges 18 years+ - NCT06692556RecruitingPhase 3
Radiation vs monitoring for high-risk skin cancer
This trial compares two strategies after surgery for a type of skin cancer (cutaneous squamous cell carcinoma) that has a high chance of coming back. One strategy gives radiation therapy to the area, while the other just watches and checks for any signs of recurrence. The goal is to see if radiation can prevent the cancer from returning.
Le Puy-en-Velay, Auvergne-Rhône-AlpesAges 18 years+ - NCT06690320Enrolling by invitation
Education program for women at high risk of breast cancer
This trial tests whether a planned education program can improve health beliefs and reduce fatalism in women who are at high risk for breast cancer. If you are 30 or older and have a high breast cancer risk score, this study may help you feel more in control of your health.
Bornova, İzmirAges 30 years+ - NCT06687551RecruitingPhase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Toulouse, OccitanieAges 18–65 - NCT06684522RecruitingEarly Phase 1
Upadacitinib for stubborn eyelid dermatitis
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
Chicago, IllinoisAges 18–70 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06689852Recruiting
Study of two treatments for nail fungus
This trial tests two different treatments for fungus that affects the fingernails or toenails. It is designed to see how well the treatments work and if they are safe.
Villeurbanne, FranceAges 18–70 - NCT06690827RecruitingPhase 1
Cd123-targeted car-nk cells for relapsed aml or bpdcn
This trial tests a new treatment using your own immune cells (natural killer cells) that are modified to find and attack cancer cells with a marker called CD123. It is for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard therapies.
Wuhan, HubeiAges 18–75
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,025 recruiting dermatology studies from the U.S. registry right now, out of 7,809 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.